Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04837651 · ClinicalTrials.gov registry record
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
A clinical trial of Multiple Sclerosis and Autoimmune Diseases, sponsored by Dragonfly Research.
- Completed
- Registry status
- 48
- Enrollment target
- 1
- Study location
NCT04837651 is a study of Multiple Sclerosis and Autoimmune Diseases that has completed, run by Dragonfly Research. The registered enrollment target is 48 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04837651, a study of Multiple Sclerosis and Autoimmune Diseases, has completed, sponsored by Dragonfly Research.
- COMPLETED
- Registry status
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this study is to provide additional data regarding B and T-cell mediated responses to COVID-19 vaccines in MS patients treated with OCR and to determine which clinical and paraclinical variables correlating with vaccine immunogenicity. B-cell mediated humoral responses and adaptive T-cell mediated cellular responses were measured in patients treated with OCR who received any of the available SARS-CoV-2 vaccines, 3-4 weeks after completion of vaccination.
Conditions Studied
Interventions
- DEVICE Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test
- DEVICE T-Detect COVID T-cell blood test
Study Locations (1)
Massachusetts
- Dragonfly Research, LLC - Wellesley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-03-02 |
| Est. Completion | 2021-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04837651
The ClinicalTrials.gov registry entry for NCT04837651 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (92% lower). The listed sponsor is Dragonfly Research, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test is the first listed.
NCT04837651 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04837651 about?
NCT04837651 is a clinical study titled "Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab". The primary goal of this study is to provide additional data regarding B and T-cell mediated responses to COVID-19 vaccines in MS patients treated with OCR and to determine which clinical and paraclinical variables correlating with vaccine immunogenicity. B-cell mediated humoral responses and adapti...
What is the current status of trial NCT04837651?
This trial is currently completed. The enrollment target is 48 participants. The study started on 2021-03-02. Estimated completion is 2021-07-01.
What conditions does trial NCT04837651 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Autoimmune Diseases, Nervous System Diseases, Immune System Diseases, Pathologic Processes.
What interventions are being tested in trial NCT04837651?
The interventions under investigation include: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test (DEVICE), T-Detect COVID T-cell blood test (DEVICE).
Who is sponsoring clinical trial NCT04837651?
This trial is sponsored by Dragonfly Research, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04837651 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.